2BBBullish & Bearish
Neurocrine Biosciences, Inc. (NBIX) trades on NASDAQ. It operates in the Health Care sector, Drug Manufacturers - Specialty & Generic industry. Its current 2BB score is 66 out of 100.
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
Neurocrine Biosciences, Inc.’s current 2BB score is 66 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 67 | High |
| Momentum | 50 | Stable |
| Financial strength | 86 | Very Strong |
| Quality | 100 | Very Strong |
| Risk | 31 | Low |
| CEO | Kevin C. Gorman |
| Headquarters | San Diego, California, United States |
| Founded | 1992 |
| Employees | 2.5K |
| P/E ratio | 22.86 |
| 52-week range | $122.14 – $186.12 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-09 | — | 1.8788 | — | $1.11B |
| 2026-10-26 | — | 1.9383 | — | $1.06B |
| 2026-07-30 | — | 1.2719 | — | $898.90M |
| 2026-05-05 | 1.91 | 1.1771 | $814.50M | $786.21M |